RxDoctor Payments Data

Aaron Fields, DO

Family Medicine · Pueblo, CONPI 1922061522

Payments from drug & device makers

$6,972in general payments, 2019–2025

Across 438 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$700
  • Novo Nordisk$681
  • Johnson & Johnson$676
  • Pfizer$434
  • GSK$254
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,950100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,972 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$77,511
Medicare patients
250
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$84,076
OzempicSemaglutide68$79,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$71,957
XareltoRivaroxaban59$60,335
TrulicityDulaglutide40$55,565
MounjaroTirzepatide46$53,248
Repatha SureclickEvolocumab51$42,431
JardianceEmpagliflozin27$32,735
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$29,661
VascepaIcosapent Ethyl36$25,838
MyrbetriqMirabegron16$20,374
FarxigaDapagliflozin Propanediol15$17,038
EntrestoSacubitril/Valsartan17$13,095
Tresiba Flextouch U-200Insulin Degludec20$10,175
Icosapent Ethyl19$8,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$97$108,81486 claims
PfizerEliquis$434$84,07678 claims
Novo NordiskOzempic$681$79,67968 claims
GSKTrelegy Ellipta$254$71,95774 claims
Johnson & JohnsonXarelto$676$60,33559 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$700$53,47260 claims
Boehringer IngelheimJardiance$80$32,73527 claims
Astellas Pharma US IncMyrbetriq$79$20,37416 claims
NovartisEntresto$23$13,09517 claims
AbbVieSynthroid$1,687$2,25939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →